BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lipworth B, Wedzicha J, Devereux G, Vestbo J, Dransfield MT. Beta-blockers in COPD: time for reappraisal. Eur Respir J 2016;48:880-8. [PMID: 27390282 DOI: 10.1183/13993003.01847-2015] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Yang YL, Xiang ZJ, Yang JH, Wang WJ, Xu ZC, Xiang RL. Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J 2020;41:4415-22. [PMID: 33211823 DOI: 10.1093/eurheartj/ehaa793] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 15.0] [Reference Citation Analysis]
2 Petta V, Perlikos F, Loukides S, Bakakos P, Chalkias A, Iacovidou N, Xanthos T, Tsekoura D, Hillas G. Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease. Heart Fail Rev 2017;22:753-63. [PMID: 28840400 DOI: 10.1007/s10741-017-9646-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Čelutkienė J, Balčiūnas M, Kablučko D, Vaitkevičiūtė L, Blaščiuk J, Danila E. Challenges of Treating Acute Heart Failure in Patients with Chronic Obstructive Pulmonary Disease. Card Fail Rev 2017;3:56-61. [PMID: 28785477 DOI: 10.15420/cfr.2016:23:2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
4 Spiesshoefer J, Regmi B, Ottaviani MM, Kahles F, Giannoni A, Borrelli C, Passino C, Macefield V, Dreher M. Sympathetic and Vagal Nerve Activity in COPD: Pathophysiology, Presumed Determinants and Underappreciated Therapeutic Potential. Front Physiol 2022;13:919422. [DOI: 10.3389/fphys.2022.919422] [Reference Citation Analysis]
5 AlHabeeb W, Mrabeti S, Abdelsalam AAI. Therapeutic Properties of Highly Selective β-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease. Cardiovasc Drugs Ther 2021. [PMID: 34106365 DOI: 10.1007/s10557-021-07205-y] [Reference Citation Analysis]
6 Leitao Filho FS, Choi L, Sin DD. Beta-blockers in chronic obstructive pulmonary disease: the good, the bad and the ugly. Curr Opin Pulm Med 2021;27:125-31. [PMID: 33332878 DOI: 10.1097/MCP.0000000000000748] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Thomas CD, Dupree LH, DeLosSantos M, Ferreira JA. Evaluation of the protective effects of β-blockers in the management of acute exacerbations of chronic obstructive pulmonary disease. J Clin Pharm Ther 2019;44:109-14. [PMID: 30311242 DOI: 10.1111/jcpt.12767] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Heriansyah T, Nur Chomsy I, Febrianda L, Farahiya Hadi T, Andri Wihastuti T. The Potential Benefit of Beta-Blockers for the Management of COVID-19 Protocol Therapy-Induced QT Prolongation: A Literature Review. Sci Pharm 2020;88:55. [DOI: 10.3390/scipharm88040055] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Kostikas K, Rhee CK, Hurst JR, Agostoni P, Cao H, Fogel R, Jones R, Kocks JWH, Mezzi K, Wan Yau Ming S, Ryan R, Price DB. Adequacy of Therapy for People with Both COPD and Heart Failure in the UK: Historical Cohort Study. Pragmat Obs Res 2020;11:55-66. [PMID: 32581622 DOI: 10.2147/POR.S250451] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agusti A. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Respirology 2017;22:575-601. [PMID: 28150362 DOI: 10.1111/resp.13012] [Cited by in Crossref: 180] [Cited by in F6Publishing: 177] [Article Influence: 36.0] [Reference Citation Analysis]
11 Maltais F, Buhl R, Koch A, Amatto VC, Reid J, Grönke L, Bothner U, Voß F, Mcgarvey L, Ferguson GT. β-Blockers in COPD. Chest 2018;153:1315-25. [DOI: 10.1016/j.chest.2018.01.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
12 Omlor AJ, Trudzinski FC, Alqudrah M, Seiler F, Biertz F, Vogelmeier CF, Welte T, Watz H, Waschki B, Brinker TJ, Andreas S, Fähndrich S, Alter P, Jörres RA, Böhm M, Bals R; German COSYCONET Cohort. Time-updated resting heart rate predicts mortality in patients with COPD. Clin Res Cardiol 2020;109:776-86. [PMID: 31734762 DOI: 10.1007/s00392-019-01572-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
13 Chaulin AM, Grigoryeva JV, Duplyakov DV. COMBORIDITY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND CARDIOVASCULAR DISEASES: GENERAL FACTORS, PATHOPHYSIOLOGICAL MECHANISMS AND CLINICAL SIGNIFICANCE. Journal of Clinical Practice. [DOI: 10.17816/clinpract21218] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
14 Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodríguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Arch Bronconeumol 2017;53:128-49. [PMID: 28274597 DOI: 10.1016/j.arbres.2017.02.001] [Cited by in Crossref: 194] [Cited by in F6Publishing: 206] [Article Influence: 38.8] [Reference Citation Analysis]
15 Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. Am J Respir Crit Care Med 2017;195:557-82. [PMID: 28128970 DOI: 10.1164/rccm.201701-0218PP] [Cited by in Crossref: 1248] [Cited by in F6Publishing: 788] [Article Influence: 249.6] [Reference Citation Analysis]
16 Sundh J, Magnuson A, Montgomery S, Andell P, Rindler G, Fröbert O; BRONCHIOLE investigators. Beta-blockeRs tO patieNts with CHronIc Obstructive puLmonary diseasE (BRONCHIOLE) - Study protocol from a randomized controlled trial. Trials 2020;21:123. [PMID: 32000825 DOI: 10.1186/s13063-019-3907-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
17 López-campos JL, Carrasco Hernández L, Quintana Gallego E. El dilema entre el pulmón y el corazón en EPOC: historia de dos ciudades. Archivos de Bronconeumología 2019;55:185-6. [DOI: 10.1016/j.arbres.2018.10.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
18 Gulea C, Zakeri R, Kallis C, Quint JK. Impact of COPD and asthma on in-hospital mortality and management of patients with heart failure in England and Wales: an observational analysis. BMJ Open 2022;12:e059122. [PMID: 35772828 DOI: 10.1136/bmjopen-2021-059122] [Reference Citation Analysis]
19 Correale M, Paolillo S, Mercurio V, Limongelli G, Barillà F, Ruocco G, Palazzuoli A, Scrutinio D, Lagioia R, Lombardi C, Lupi L, Magrì D, Masarone D, Pacileo G, Scicchitano P, Matteo Ciccone M, Parati G, Tocchetti CG, Nodari S. Comorbidities in chronic heart failure: An update from Italian Society of Cardiology (SIC) Working Group on Heart Failure. European Journal of Internal Medicine 2020;71:23-31. [DOI: 10.1016/j.ejim.2019.10.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
20 Villgran V, Gordon A, Malik K, Cheema T. Comorbidities Associated With Chronic Obstructive Pulmonary Disease. Crit Care Nurs Q 2021;44:103-12. [PMID: 33234863 DOI: 10.1097/CNQ.0000000000000343] [Reference Citation Analysis]
21 Suissa S, Ernst P. Beta-Blockers in COPD: A Methodological Review of the Observational Studies. COPD 2018;15:520-5. [PMID: 30822238 DOI: 10.1080/15412555.2018.1554637] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
22 Chaulin AM, Duplyakov DV. Cardiovascular diseases and chronic obstructive pulmonary disease: etiopathogenetic relationship and clinical signifi cance (literature review). SMJ 2020;35:26-34. [DOI: 10.29001/2073-8552-2020-35-2-26-34] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
23 Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, Varela MVL, Nishimura M, Roche N, Rodriguez-roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agusti A. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Archivos de Bronconeumología (English Edition) 2017;53:128-49. [DOI: 10.1016/j.arbr.2017.02.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 9] [Article Influence: 5.2] [Reference Citation Analysis]
24 Scrutinio D, Guida P, Passantino A, Ammirati E, Oliva F, Lagioia R, Raimondo R, Venezia M, Frigerio M. Acutely decompensated heart failure with chronic obstructive pulmonary disease: Clinical characteristics and long-term survival. Eur J Intern Med 2019;60:31-8. [PMID: 30446355 DOI: 10.1016/j.ejim.2018.11.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
25 Park YB, Rhee CK, Yoon HK, Oh YM, Lim SY, Lee JH, Yoo KH, Ahn JH; Committee of the Korean COPD Guideline 2018. Revised (2018) COPD Clinical Practice Guideline of the Korean Academy of Tuberculosis and Respiratory Disease: A Summary. Tuberc Respir Dis (Seoul) 2018;81:261-73. [PMID: 29926554 DOI: 10.4046/trd.2018.0029] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
26 Mirza S, Clay RD, Koslow MA, Scanlon PD. COPD Guidelines: A Review of the 2018 GOLD Report. Mayo Clin Proc. 2018;93:1488-1502. [PMID: 30286833 DOI: 10.1016/j.mayocp.2018.05.026] [Cited by in Crossref: 128] [Cited by in F6Publishing: 114] [Article Influence: 42.7] [Reference Citation Analysis]
27 Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis 2018;12:1753465817750524. [PMID: 29355081 DOI: 10.1177/1753465817750524] [Cited by in Crossref: 70] [Cited by in F6Publishing: 61] [Article Influence: 23.3] [Reference Citation Analysis]
28 Chapman KR, Wise RA, Scirica BM, Bhatt DL, Daoud SZ, Lythgoe D, Gil EG. Long-acting antimuscarinic therapy in patients with chronic obstructive pulmonary disease receiving beta-blockers. Respir Res 2021;22:272. [PMID: 34686204 DOI: 10.1186/s12931-021-01861-2] [Reference Citation Analysis]
29 Leong P, Macdonald MI, Ko BS, Bardin PG. Coexisting chronic obstructive pulmonary disease and cardiovascular disease in clinical practice: a diagnostic and therapeutic challenge. Medical Journal of Australia 2019;210:417-23. [DOI: 10.5694/mja2.50120] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
30 D'Urzo AD, Singh D, Donohue JF, Chapman KR, Wise RA. Aclidinium bromide/formoterol fumarate as a treatment for COPD: an update. Expert Rev Respir Med 2021;:1-14. [PMID: 34137664 DOI: 10.1080/17476348.2021.1920403] [Reference Citation Analysis]
31 Schäper C, Ittermann T, Gläser S, Dörr M, Völzke H, Stubbe B, Felix SB, Ewert R, Bollmann T. The Correlation of Lung Function Parameters, Blood Pressure and Beta-Blocker Medication in a General Population. Pneumologie 2021. [PMID: 34341979 DOI: 10.1055/a-1545-3337] [Reference Citation Analysis]
32 Stratev V, Dimitrova V, Petkova D. COPD and Comorbidities: Relating Mechanisms and Treatment. CRMR 2019;15:90-101. [DOI: 10.2174/1573398x14666181018101021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
33 Low B, Shah M, Nassour V, Fox K. Acute management of atrial fibrillation with rapid ventricular response. Br J Hosp Med (Lond) 2019;80:C82-5. [PMID: 31180774 DOI: 10.12968/hmed.2019.80.6.C82] [Reference Citation Analysis]
34 Neef PA, Burrell LM, Mcdonald CF, Irving LB, Johnson DF, Steinfort DP. Commencement of cardioselective beta-blockers during hospitalisation for acute exacerbations of chronic obstructive pulmonary disease: β-blockers in acute exacerbation of COPD. Intern Med J 2017;47:1043-50. [DOI: 10.1111/imj.13518] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
35 Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agusti A. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Eur Respir J 2017;49:1700214. [PMID: 28182564 DOI: 10.1183/13993003.00214-2017] [Cited by in Crossref: 343] [Cited by in F6Publishing: 348] [Article Influence: 68.6] [Reference Citation Analysis]
36 Pajouheshnia R, Schuster NA, Groenwold RHH, Rutten FH, Moons KGM, Peelen LM. Accounting for time‐dependent treatment use when developing a prognostic model from observational data: A review of methods. Statistica Neerlandica 2019. [DOI: 10.1111/stan.12193] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
37 Jabbal S, Anderson W, Short P, Morrison A, Manoharan A, Lipworth BJ. Cardiopulmonary interactions with beta-blockers and inhaled therapy in COPD. QJM 2017;110:785-92. [PMID: 29025008 DOI: 10.1093/qjmed/hcx155] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
38 Agabiti N, Corbo GM. COPD and bronchodilators: should the heart pay the bill for the lung? Eur Respir J 2017;49:1700370. [PMID: 28536252 DOI: 10.1183/13993003.00370-2017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
39 Lopez-campos JL, Márquez-martín E, Casanova C. Beta-blockers and COPD: the show must go on. Eur Respir J 2016;48:600-3. [DOI: 10.1183/13993003.01222-2016] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
40 Onishi K. Total management of chronic obstructive pulmonary disease (COPD) as an independent risk factor for cardiovascular disease. J Cardiol 2017;70:128-34. [PMID: 28325523 DOI: 10.1016/j.jjcc.2017.03.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
41 Zhukov KV, Vetcher AA, Gasparuan BA, Shishonin AY. Alteration of Relative Rates of Biodegradation and Regeneration of Cervical Spine Cartilage through the Restoration of Arterial Blood Flow Access to Rhomboid Fossa: A Hypothesis. Polymers (Basel) 2021;13:4248. [PMID: 34883749 DOI: 10.3390/polym13234248] [Reference Citation Analysis]
42 Vahdatpour CA, Luebbert JJ, Palevsky HI. Atrial arrhythmias in chronic lung disease-associated pulmonary hypertension. Pulm Circ 2020;10:2045894020910685. [PMID: 32215200 DOI: 10.1177/2045894020910685] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Leitao Filho FS, Alotaibi NM, Yamasaki K, Ngan DA, Sin DD. The role of beta-blockers in the management of chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine 2017;12:125-35. [DOI: 10.1080/17476348.2018.1419869] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]